Monoamine Oxidases and Their Selective Inhibition (eBook)

Proceedings of the 3rd Congress of the Hungarian Pharmacological Society, Budapest, 1979

K. Magyar (Herausgeber)

eBook Download: PDF

2013 | 1. Auflage
170 Seiten
Elsevier Science (Verlag)
978-1-4831-4786-4 (ISBN)

Infos

Monoamine Oxidases and Their Selective Inhibition, Volume IV, documents the proceedings of the 3rd Congress of the Hungarian Pharmacological Society held in Budapest, 1979. The discovery of the selective monoamine oxidase (MAO) inhibitors, such as clorgyline and deprenyl, has given a new impetus to MAO research as well as to the clinical applicability of these compounds. This volume contains 21 papers by researchers and clinicians from eight different countries. It begins with papers on the pharmacological effects and the biochemical mode of actions of deprenyl as well as some other new selective inhibitors. This is followed by communications concerning the biochemical methods applied in the study of the nature of MAO in the mitochondrial membrane. Finally, the neurologists provide an account of their experience with the clinical application of deprenyl, and other inhibitors in Parkinsonian patients. They also discuss the essential role of the dopaminergic mechanism with respect to the disease.

Inhalt

Front Cover 1
Monoamine Oxidases and Their Selective Inhibition 4
Copyright Page 5
Table of Contents 6
PREFACE 8
LIST OF CONTRIBUTORS 10
CHAPTER 1. THE ANALYSIS OF AMINE OXIDASES BY THE USE OF ENZYMEINHIBITORS 12
References 14
CHAPTER 2. RECENT CLINICAL STUDIES IN MONOAMINE OXIDASE INHIBITION 16
References 20
CHAPTER 3. STRUCTURE-ACTIVITY RELATIONSHIP OF SELECTIVE INHIBITORSOF MAO-B 22
Introduction 22
Methods 23
Results and discussion 24
References 31
CHAPTER 4. SELECTIVE INHIBITORS OF MAO-B WITH DIFFERENT PHARMACOLOGICALPROFILES 34
(-)Deprenyl, a MAO inhibitor which reduces the pressor effectof tyramine 36
-(-)Deprenyl reduces the release of noradrenaline from the nerveterminals 38
(-)Deprenyl is a poor inhibitor of intestinal MAO 40
REFERENCES 46
CHAPTER 5. 13 METHAMPHETAMINE A THBRAHfiUTIDALLY IMPORTANT METABOLITE OF JSPRENiL? 48
References 50
CHAPTER 6 
52 
Introduction 52
Material and Method 52
Results 53
Discussion 54
Summary 55
References 55
CHAPTER 7. DEPRENYL INHIBITS DOPAMINE UPTAKE IN THE RAT STRIATUM IN VIVO 56
Introduction 56
Materials and Methods 57
Results 58
Discussion 60
Conclusion 63
References 63
CHAPTER 8. GEL CHROMATOGRAPHY OF PHENYLALKYLAMINES 68
SUMMARY 68
INTRODUCTION 68
RESULTS 69
COMMENTS 74
REFERENCES 74
CHAPTER 9. Human platelet MAO-B - one single enzyme form? 76
Introduction 76
Materials and Methods 77
Results and Discussion 78
Acknowledgements 81
Summary 81
References 82
CHAPTER 10. SUICIDE INHIBITORS OF MONOAMINE OXIDASE1 84
A. Acetylenic amines 85
B. Allenic amines 88
C. Cyclopropy1amines 90
D. Arylhydrazines 92
REFERENCES 95
chapter 11. PURIFICATION AND PROPERTIES OP THE PHENYLHYDRAZINE ADDUCTSOP TRIMETHYLAMINE DEHYDROGENASE AND OP MONOAMINE OXIDASE 96
Introduction 96
Materials and Methods 97
Results and Discussion 97
Summary 103
References 104
CHAPTER 12. SELECTIVE INHIBITION OF MAO INDUCED BY NEW ANTIDEPRESSANTDERIVATIVES OF PYRAZINE-INDOLE 106
Introduction 106
Material and methods 107
Results 108
Discussion 111
Summary 112
References 113
CHAPTER 13. SELECTIVE INHIBITION OF MONOAMINE OXIDASE TYPE A BY SOME4-AMINOPHENYLISOPROPYLAMINE COMPOUNDS 114
MATERIALS AND METHODS 114
RESULTS 115
DISCUSSION 116
SUMMARY 117
REFERENCES 117
CHAPTER 14. THIOL COMPOUNDS AND MDNOAMINE OXIDASE IN RAT LIVER AND BRAIN 118
METHODS 118
RESULTS 119
DISCUSSION 120
SUMMARY 121
REFERENCES 121
CHAPTER 15. ENZYME STIMULATION AMD INHIBITION AS AN APPROACH TOTHERAPY FOR PARKINSON'S DISEASE 122
References 126
CHAPTER 16. PHARMACO-THERAPY OF PARKINSONISM 128
Summary 135
References 136
CHAPTER 17.LINICAL EXPERIENCE IN EXTRAPYRAMIDAL DISEASE WITH SELECTIVEMAO - BINHIBITOR , DEPRENYL 138
References 143
CHAPTER 18. (-)DEPRENYL HAS A BAND OF SELECTIVITY FOR THERAPEUTIC ACTION 144
References 148
CHAPTER 19. THE NNACTION OF L- DEPRENYLINL - DOPA TREATED PARKINSONI ANPATIENTS , WITHSPECIAL REFERENCE TO THE1ON- OFF1EF FECT 150
INTRODUCTIOIN 150
RESULTS 151
SIDE EFFECTS 151
DISCUSSION 153
SUMMARY 153
ACKNOWLEDGEMENT 154
REFERENCES 154
CHAPTER 20. LONG-TERM L-DEPRENYL TREATMENT OF ON-OFF PHENOMENA IN PARKINSON'S DISEASE 156
INTRODUCTION 156
MATERIAL AND METHODS 156
RESULTS 157
CONCLUSIONS 158
SUMMARY 159
REFERENCES 159
ACKNOWLEDGEMENTS 160
CHAPTER 21. LATE KINETIC EFFECTS OF L-DOPA AND COMBINED THERAPYIN PARKINSON'S DISEASE 162
Material and methods 162
Results 163
Comments 168
Summary 168
References 169
SUBJECT INDEX 170

Produkt-Details

• Erscheint lt. Verlag: 22.10.2013
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Schmerztherapie
• Themenwelt: Studium ► 2. Studienabschnitt (Klinik) ► Pharmakologie / Toxikologie
• ISBN-10: 1-4831-4786-X / 148314786X
• ISBN-13: 978-1-4831-4786-4 / 9781483147864